tirzepatide trial sign up Shows Superior Weight Loss Over Semaglutide in Phase 3 New research from the SURPASS-EARLY

A thriving gut microbiome is the foundation of vitality, making this the perfect addition to your daily wellness routine

Accurately personalized

Geier DA, Geier MR: A clinical and laboratory evaluation of methionine cycle-transsulfuration and androgen pathway markers in children with autistic disorders

Findings Participants and Intervention: Between October 5, 2018, and February 1, 2019, 304 individuals were randomly assigned to either receive semaglutide 2.4 mg (n = 152) or placebo (n = 152) and were encompassed in the comprehensive analysis set (comprising all randomized individuals as per the intention-to-treat principle)